Unknown

Dataset Information

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.


ABSTRACT:

SUBMITTER: Popat R 

PROVIDER: S-EPMC11494064 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature